August 29, 2018 06:59 AM EDT

As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype

John Carroll

Editor & Founder

The Hong Kong Exchange grabbed the biotech world’s attention when it changed the rules on a new listing, letting companies without revenue jump into the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL

As the maid­en biotech IPO on the HKEX fiz­zles, some in­vest­ment ex­perts see an up­side in tem­per­ing the hype

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

As the maiden biotech IPO on the HKEX fizzles, some investment experts see an upside in tempering the hype

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Bristol Myers sues the federal government over 340B, following other drugmakers

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Applied Therapeutics' rare disease drug gets a CRL